The necessary regulatory filings, EDMF and CEP, have been made with the relevant authorities. This latest addition to Chemoswed’s commercial line of products is applied in a fixed dose combination with L-dopa, serving to minimise systemic side effects in Parkinson’s disease patients.
Said Carl Andersson, marketing manager at Chemoswed:
Benserazide represents a great business opportunity for us on a pretty poorly supported generics market. While benserazide hydrochloride is rather demanding from a process point of view, our development over the last few years has established a product of superior quality which we are keen to offer to European customers at competitive prices.